cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4524260
title: Dataset for publication DOI: 10.1007/s00787-020-01582-9

description: linked publication Eur Child Adolesc Psychiatry. 2020 Jul 2. doi: 10.1007/s00787-020-01582-9. Online ahead of print. Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression Marco Pozzi<sup> 1</sup>, Roberta Ida Ferrentino<sup> 2</sup>, Giulia Scrinzi<sup> 3</sup>, Cristina Scavone<sup> 4</sup>, Annalisa Capuano<sup> 4</sup>, Sonia Radice<sup> 5</sup>, Maria Nobile<sup> 1</sup>, Pietro Formisano<sup> 2</sup>, Emilio Clementi<sup> 5</sup>, Carmela Bravaccio<sup> 2</sup>, Carla Carnovale<sup> 6</sup>, Simone Pisano<sup> 2 7</sup> PMID: <strong>32617775</strong> DOI: 10.1007/s00787-020-01582-9
description: Funded by Ministero della Salute - Ricerca Corrente 2020, to Marco Pozzi
DOI: 10.6084/m9.figshare.13303433
title: Proportions spreadsheet for 'Surface mines show little progress towards native species forest restoration following 35 years of passive management after initial reclamation'

description: This spreadsheet contain proportional data for various species characteristics and was used to run linear models to test for an effect of age. Methodology can be found in the Methods section of the manuscript.
DOI: 10.6084/m9.figshare.13303433.v1
title: Proportions spreadsheet for 'Surface mines show little progress towards native species forest restoration following 35 years of passive management after initial reclamation'

description: This spreadsheet contain proportional data for various species characteristics and was used to run linear models to test for an effect of age. Methodology can be found in the Methods section of the manuscript.
DOI: 10.6084/m9.figshare.13266995
title: Survey Matrix for 'Surface mines show little progress towards native species forest restoration following 35 years of passive management after initial reclamation'

description: This spreadsheet contains the Site X Species matrix and the factor 'age' used to conduct statistical analyses for the project. Methodology pertaining to the collection of these data or statistical analyses conducted on them can be found in the manuscript.
DOI: 10.5281/zenodo.4524361
title: Dataset for publication DOI: 10.1080/14728214.2020.1820481

description: linked publication Expert Opin Emerg Drugs. 2020 Dec;25(4):395-407. doi: 10.1080/14728214.2020.1820481. Epub 2020 Sep 25. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD) Marco Pozzi<sup> 1</sup>, Silvana Bertella<sup> 1</sup>, Erika Gatti<sup> 1</sup>, Gabriëlla G A M Peeters<sup> 2</sup>, Carla Carnovale<sup> 2</sup>, Stefania Zambrano<sup> 1 3</sup>, Maria Nobile<sup> 1</sup> PMID: <strong>32938246</strong> DOI: 10.1080/14728214.2020.1820481
description: Funded by Ministero della Salute (Ricerca Corrente 2020, to Marco Pozzi)
DOI: 10.5281/zenodo.4524360
title: Dataset for publication DOI: 10.1080/14728214.2020.1820481

description: linked publication Expert Opin Emerg Drugs. 2020 Dec;25(4):395-407. doi: 10.1080/14728214.2020.1820481. Epub 2020 Sep 25. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD) Marco Pozzi<sup> 1</sup>, Silvana Bertella<sup> 1</sup>, Erika Gatti<sup> 1</sup>, Gabriëlla G A M Peeters<sup> 2</sup>, Carla Carnovale<sup> 2</sup>, Stefania Zambrano<sup> 1 3</sup>, Maria Nobile<sup> 1</sup> PMID: <strong>32938246</strong> DOI: 10.1080/14728214.2020.1820481
description: Funded by Ministero della Salute (Ricerca Corrente 2020, to Marco Pozzi)
DOI: 10.15468/xw3nsd
title: New records, a completed list and identification key of mites (Acari) associated with the stable fly, Stomoxys calcitrans (L.) (Diptera: Muscidae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Kontschán, Jenő, Hornok, Sándor (2019): New records, a completed list and identification key of mites (Acari) associated with the stable fly, Stomoxys calcitrans (L.) (Diptera: Muscidae). Acarologia 59 (1): 3-11, DOI: 10.24349/acarologia/20194306, URL: http://dx.doi.org/10.24349/acarologia/20194306
DOI: 10.5281/zenodo.4524533
title: Data for "Transient CO Desorption From Thin Pt Films Induced by Mid-IR Pumping"

description: Data used for the figures on the main manuscript and supplementary materials.
DOI: 10.5281/zenodo.4524532
title: Data for "Transient CO Desorption From Thin Pt Films Induced by Mid-IR Pumping"

description: Data used for the figures on the main manuscript and supplementary materials.
DOI: 10.5281/zenodo.4518700
title: Dataset related to the article "Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies"

description: This record contains data related to article "Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies". <strong>Objectives: </strong> Serum autoantibodies are pivotal for the early detection of systemic autoimmune rheumatic diseases such as Systemic Sclerosis (SSc) and Poly/Dermatomyositis (PM/DM), and in some cases are associated with organ complications such as interstitial lung disease (ILD). A paradigmatic example is provided by the autoantibody against the Eukaryotic Initiation Factor 2B (eIF2B) that has been recently detected in SSc. <strong>Methods: </strong> Sera from 118 patients with SSc, 8 Poly/Dermatomyositis, 2 overlap SSc/Polymyositis, 4 undifferentiated connective tissue disease-UCTD and 3 healthy controls were tested first by indirect immunofluorescence for anti-nuclear antibodies-ANA pattern. Further, we employed protein-radioimmunoprecipitation (IP) and IP- Western Blot for the detection and confirmation of anti-eIF2B antibodies. Serum findings were further correlated with the clinical features of patients. <strong>Results: </strong> We identified 3 SSc cases (2.5%) positive for anti-eIF2B antibodies while this autoantibody was not detected in control sera. Using protein-IP all three patients manifested the 38kD protein which is the antigenic target of anti-eIF2B antibodies, and this was associated with a cytoplasmic pattern at indirect immunofluorescence. The presence of anti-eIF2B was associated with ILD and a diffuse SSc variant, in one case in association with anti-Scl70/topoI. <strong>Conclusions: </strong> Our data confirm that a small subgroup (2.5%) of patients with SSc have detectable anti-eIF2B with cytoplasmic-positive staining at immunofluorescence and this reactivity is associated with ILD.
DOI: 10.5281/zenodo.4518699
title: Dataset related to the article "Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies"

description: This record contains data related to article "Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies". <strong>Objectives: </strong> Serum autoantibodies are pivotal for the early detection of systemic autoimmune rheumatic diseases such as Systemic Sclerosis (SSc) and Poly/Dermatomyositis (PM/DM), and in some cases are associated with organ complications such as interstitial lung disease (ILD). A paradigmatic example is provided by the autoantibody against the Eukaryotic Initiation Factor 2B (eIF2B) that has been recently detected in SSc. <strong>Methods: </strong> Sera from 118 patients with SSc, 8 Poly/Dermatomyositis, 2 overlap SSc/Polymyositis, 4 undifferentiated connective tissue disease-UCTD and 3 healthy controls were tested first by indirect immunofluorescence for anti-nuclear antibodies-ANA pattern. Further, we employed protein-radioimmunoprecipitation (IP) and IP- Western Blot for the detection and confirmation of anti-eIF2B antibodies. Serum findings were further correlated with the clinical features of patients. <strong>Results: </strong> We identified 3 SSc cases (2.5%) positive for anti-eIF2B antibodies while this autoantibody was not detected in control sera. Using protein-IP all three patients manifested the 38kD protein which is the antigenic target of anti-eIF2B antibodies, and this was associated with a cytoplasmic pattern at indirect immunofluorescence. The presence of anti-eIF2B was associated with ILD and a diffuse SSc variant, in one case in association with anti-Scl70/topoI. <strong>Conclusions: </strong> Our data confirm that a small subgroup (2.5%) of patients with SSc have detectable anti-eIF2B with cytoplasmic-positive staining at immunofluorescence and this reactivity is associated with ILD.
DOI: 10.5281/zenodo.4518785
title: Dataset related to article "Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study"

description: This record contains data related to article "Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study". <strong>Objectives: </strong> Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life. <strong>Methods: </strong> We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC). <strong>Results: </strong> Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation. <strong>Conclusions: </strong> Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients
DOI: 10.5281/zenodo.4518784
title: Dataset related to article "Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study"

description: This record contains data related to article "Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study". <strong>Objectives: </strong> Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life. <strong>Methods: </strong> We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC). <strong>Results: </strong> Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation. <strong>Conclusions: </strong> Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients
DOI: 10.5281/zenodo.4519138
title: Dataset related to article "Rheumatoid factor and anti-citrullinated peptide antibodies in the general population: hepatitis B and C virus association and 15-year-risk of rheumatoid arthritis "

description: This record contains data related to the article "Rheumatoid factor and anti-citrullinated peptide antibodies in the general population: hepatitis B and C virus association and 15-year-risk of rheumatoid arthritis". <strong>Objectives: </strong> The study aimed to determine the prevalence of rheumatoid factor (RF) and anti-citrullinated peptides (ACPA), to estimate the association with hepatitis B (HBV) or C (HCV) virus infections and the 15-year risk of developing RA in a large cohort from a Northern Italian region. <strong>Methods: </strong> In 1998, 15,907 subjects between the ages of 18 and 75 were randomly selected 1:4 for HBV and HCV testing; more recently, we tested a subgroup of sera for RF (n=2196) and ACPA (n=2525). Administrative databases were searched after 15 years for incident RA diagnoses occurring between 1998 and 2013. <strong>Results: </strong> RF was positive in 8.1% of cases with 10% of RF-positive subjects having HBsAg (p=0.004) and 9% anti-HCV. ACPA were detected in 4.8% of subjects with 5% of the ACPA-positive subjects having HBsAg and 5.9% anti-HCV. Older subjects had higher positivity rates for both RF and ACPA. HBsAg and anti-HCV were detected in 5.5% and 4.3% of sera, respectively. Over 15 years, 10 RA cases were recorded (9 women, median age at diagnosis 52 years) with RF previously positive in 2/10 and ACPA in 5/10 cases. RF and ACPA were associated with relative risks for developing RA of 5.7 (adjusted for HBsAg status; 95% CI 1.2-26.3) and 13.2 (95% CI 3.8-46.3), respectively. <strong>Conclusions: </strong> Our data in a large cohort from an unselected general population confirm a higher risk of RA development associated with ACPA compared to RF. HBV exposure correlates with RF but not with ACPA positivity.
DOI: 10.5281/zenodo.4519137
title: Dataset related to article "Rheumatoid factor and anti-citrullinated peptide antibodies in the general population: hepatitis B and C virus association and 15-year-risk of rheumatoid arthritis "

description: This record contains data related to the article "Rheumatoid factor and anti-citrullinated peptide antibodies in the general population: hepatitis B and C virus association and 15-year-risk of rheumatoid arthritis". <strong>Objectives: </strong> The study aimed to determine the prevalence of rheumatoid factor (RF) and anti-citrullinated peptides (ACPA), to estimate the association with hepatitis B (HBV) or C (HCV) virus infections and the 15-year risk of developing RA in a large cohort from a Northern Italian region. <strong>Methods: </strong> In 1998, 15,907 subjects between the ages of 18 and 75 were randomly selected 1:4 for HBV and HCV testing; more recently, we tested a subgroup of sera for RF (n=2196) and ACPA (n=2525). Administrative databases were searched after 15 years for incident RA diagnoses occurring between 1998 and 2013. <strong>Results: </strong> RF was positive in 8.1% of cases with 10% of RF-positive subjects having HBsAg (p=0.004) and 9% anti-HCV. ACPA were detected in 4.8% of subjects with 5% of the ACPA-positive subjects having HBsAg and 5.9% anti-HCV. Older subjects had higher positivity rates for both RF and ACPA. HBsAg and anti-HCV were detected in 5.5% and 4.3% of sera, respectively. Over 15 years, 10 RA cases were recorded (9 women, median age at diagnosis 52 years) with RF previously positive in 2/10 and ACPA in 5/10 cases. RF and ACPA were associated with relative risks for developing RA of 5.7 (adjusted for HBsAg status; 95% CI 1.2-26.3) and 13.2 (95% CI 3.8-46.3), respectively. <strong>Conclusions: </strong> Our data in a large cohort from an unselected general population confirm a higher risk of RA development associated with ACPA compared to RF. HBV exposure correlates with RF but not with ACPA positivity.
DOI: 10.6084/m9.figshare.13738657.v2
title: Abundance imparts evolutionary constraints of similar magnitude on the buried, surface, and disordered regions of proteins

description: Here, we integrate residue-level and protein-level data for different structural regions such as: disordered regions, structured domains, surface and buried residues. <br><br>These datasets serve the analysis of evolutionary constraints within-and-across structural regions of yeast proteins, and were analyzed in a manuscript submitted to Frontiers Molecular Biosciences entitled "Abundance imparts evolutionary constraints of similar magnitude on the buried, surface, and disordered regions of proteins"<br><br>The proteins sequences were taken from the reference S. cerevisiae proteome from SGD, filtering for proteins with known orthologs in 14 fungi species, as defined in Wapinsky et al., Nature (2007).<br><br>Two datasets were used for our analysis: - a protein-centric dataset (PROTEIN-EVORATE.tsv)<br>- a residue-centric dataset (RESIDUE-EVORATE.tsv)<br><br>Both datasets are available as regular data table formatted to Tab Separated Value (TSV). <br><br>At the residue level, 42 features are mapped on 2,129,854 residues comprising 3797 unique proteins.<br>At the protein level, 25 features are calculated for 3797 unique proteins.<br><br>Each feature is described in a text file distributed along the datasets (starting with "header-").<br>
DOI: 10.25375/uct.13773505
title: Excel-based supply-use analysis for South African GHG household emissions inequality estimation

description: Excel-based supply-use table multiplier analysis of South African household carbon intensity measures and emissions to determine household responsibility for climate change mitigation action at an intra-national level. This dataset draws on a preliminary household classification on the basis of per capita expenditure and income, linked to full expenditures from the Income and Expenditure Surveys for 2005/6 and 2010/11 and the Living Conditions Survey for 2015 conducted by StatsSA.<br>SUT multiplier analysis is demonstrated in Excel workbooks for each year, with integrated analysis and responsibility measures.<br>This dataset and analysis are the underlying calculations for a minor dissertation as part of the ACDI MSc in Climate and Development: "<i>Income inequality and mitigation burdens: An examination of climate mitigation fair shares for South African households</i>" by James Reeler <br>All data are derived from publicly-available datasets, and are referenced in the thesis document as well as within the files themselves.<br>Files present: 1. 2005 SUT analysis.xlsx: Multiplier analysis for 20052. 2010 SUT analysis.xlsx: Multiplier analysis for 20103. 2015 SUT analysis.xlsx: Multiplier analysis for 20154. Analysis final.xlsx: Tables and graphs for integration into thesis5. SNA equivalencies.xlsx: Tables to enable conversion of SNA 1993 SIC classes (171 industry) to current 64 industry classes.6. CIOCOP-SU-CPC.xlsx: Tables to enable allocation of COICOP classes from IES/LCS to relevant CPC and supply-use SIC classifications. Includes automated classification with supplementary manual classification where necessary, and is limited primarily to consumption classes. <br>Excel version: Microsoft 365 Excel version 2102 (Build 13801.20004)
DOI: 10.25375/uct.13773505.v1
title: Excel-based supply-use analysis for South African GHG household emissions inequality estimation

description: Excel-based supply-use table multiplier analysis of South African household carbon intensity measures and emissions to determine household responsibility for climate change mitigation action at an intra-national level. This dataset draws on a preliminary household classification on the basis of per capita expenditure and income, linked to full expenditures from the Income and Expenditure Surveys for 2005/6 and 2010/11 and the Living Conditions Survey for 2015 conducted by StatsSA.<br>SUT multiplier analysis is demonstrated in Excel workbooks for each year, with integrated analysis and responsibility measures.<br>This dataset and analysis are the underlying calculations for a minor dissertation as part of the ACDI MSc in Climate and Development: "<i>Income inequality and mitigation burdens: An examination of climate mitigation fair shares for South African households</i>" by James Reeler <br>All data are derived from publicly-available datasets, and are referenced in the thesis document as well as within the files themselves.<br>Files present: 1. 2005 SUT analysis.xlsx: Multiplier analysis for 20052. 2010 SUT analysis.xlsx: Multiplier analysis for 20103. 2015 SUT analysis.xlsx: Multiplier analysis for 20154. Analysis final.xlsx: Tables and graphs for integration into thesis5. SNA equivalencies.xlsx: Tables to enable conversion of SNA 1993 SIC classes (171 industry) to current 64 industry classes.6. CIOCOP-SU-CPC.xlsx: Tables to enable allocation of COICOP classes from IES/LCS to relevant CPC and supply-use SIC classifications. Includes automated classification with supplementary manual classification where necessary, and is limited primarily to consumption classes. <br>Excel version: Microsoft 365 Excel version 2102 (Build 13801.20004)
DOI: 10.15468/qf8uqa
title: Holarktische Bienenarten - autochthon, eingeführt, eingeschleppt

description: This dataset contains the digitized treatments in Plazi based on the original journal article Ebmer, A. W. (2011): Holarktische Bienenarten - autochthon, eingeführt, eingeschleppt. Linzer biologische Beiträge 43 (1): 5-83, DOI: http://doi.org/10.5281/zenodo.4524335
DOI: 10.15468/zpqkbm
title: Complementary description of Podocinella misella (Berlese, 1913) (Acari: Podocinidae) and a key to world species of the genus

description: This dataset contains the digitized treatments in Plazi based on the original journal article Santos, Jandir C., Mineiro, Jeferson L. de C., de Moraes, Gilberto J. (2019): Complementary description of Podocinella misella (Berlese, 1913) (Acari: Podocinidae) and a key to world species of the genus. Acarologia 59 (2): 181-187, DOI: 10.24349/acarologia/20194321, URL: http://dx.doi.org/10.24349/acarologia/20194321
DOI: 10.15468/cqu6bj
title: A new species of Cheletonella Womersley (Prostigmata: Cheyletidae) from Iran and a key to the species

description: This dataset contains the digitized treatments in Plazi based on the original journal article Salarzehi, Safoura, Hajizadeh, Jalil, Ueckermann, Edward A. (2019): A new species of Cheletonella Womersley (Prostigmata: Cheyletidae) from Iran and a key to the species. Acarologia 59 (2): 188-195, DOI: 10.24349/acarologia/20194323, URL: http://dx.doi.org/10.24349/acarologia/20194323
DOI: 10.5281/zenodo.4524643
title: Data and scripts used in Bayesian forecasting of coral bleaching in Abrolhos - Brazil

description: This repository contains numerical data on seawater parameters, reef monitoring field data, and Matlab scripts used for the construction of the conceptual model for short-term forecasting of coral bleaching in the Atlantic Ocean.